Supplementary Information
B-cell malignancies
Tirabrutinib is a Bruton’s tyrosine kinase inhibitor for treating B-cell malignancies. We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. Patients were administered tirabrutinib at a dose of 160 mg, 320 mg, or 480 mg once daily, or 300 mg twice daily (Clinical trial registration: JapicCTI-142682 (The online version contains supplementary material available at 10.1007/s12185-022-03514-6.